Recent studies have reported that elevated levels of galectin-7 in different types of cancer. The mechanisms underlying its abnormal regulation in cancer cells remain, however, unknown. Here, we have examined the relationship between galectin-7 and p53, a gene previously associated with upregulation of galectin-7. While RNA and protein analyses revealed a consistent and irreversible upregulation of galectin-7 throughout progression of lymphoma, no correlation with p53 was found. In fact, most of the lymphoma cell lines expressing high levels of galectin-7 did not express any detectable level of p53, although expressed p21Waf1/Cip1gene following doxorubicin treatment, indicating that p53 was functional in these cells. Methylation-specific polymerase chain reaction (MS-PCR) analyses rather suggested that galectin-7 expression was associated with changes in DNA methylation. This conclusion was supported by data using demethylating agent 5-aza-dC. Furthermore, disruption of the DNA methylases dnmt1 and dnmt3a induced galectin-7. Collectively, our data suggest that abnormal expression of galectin-7 in lymphoma cells is not dependent on p53, but is rather associated with DNA hypomethylation.

, , ,,
Biochemical and Biophysical Research Communications
Erasmus MC: University Medical Center Rotterdam

Demers, M., Couillard, J., Giglia-Mari, G., Magnaldo, T., & St-Pierre, Y. (2009). Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation. Biochemical and Biophysical Research Communications, 387(3), 425–429. doi:10.1016/j.bbrc.2009.07.015